This is a discussion on TA143: Ankylosing spondylitis - adalimumab, etanercept and infliximab within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Ankylosing spondylitis - adalimumab, etanercept and infliximab. It links to the published guidance ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
|
|||
|
The summary for the published technology appraisal on Ankylosing spondylitis - adalimumab, etanercept and infliximab. It links to the published guidance and key documents.
More... |
![]() |
| Thread Tools | |
| Display Modes | |
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| Biologic agents for ankylosing spondylitis - policy criteria | chantell.reagan | Managed Care Issues for Injectable Drugs | 0 | 02-19-2009 10:34 AM |
| Infliximab Improves Symptoms of Ankylosing Spondylitis, but Damage Continues | industry_news | Other Clinical Pharmacy News | 0 | 11-03-2008 02:20 PM |
| Adalimumab and Etanercept Edge Infliximab in RA Therapy | industry_news | Other Clinical Pharmacy News | 0 | 09-18-2008 01:17 PM |
| Long-Term Adalimumab May Be Helpful in Ankylosing Spondylitis | industry_news | Other Clinical Pharmacy News | 0 | 08-18-2008 06:30 PM |